![Western Blot: USF2 Antibody [NBP1-92649] - Detection of human USF2 by western blot and immunoprecipitation. Samples: Whole cell lysate from HeLa (15 and 50 ug for WB; 1 mg for IP, 20% of IP loaded), HEK293T (T; 50 ug) and Jurkat (J; 50 ug) cells. Antibodies: Affinity purified rabbit anti-USF2 antibody NBP1-92649 used for WB at 0.1 ug/ml (A) and 1 ug/ml (B) and used for IP at 6 ug/mg lysate. USF2 was also immunoprecipitated by rabbit anti-USF2 antibodies NBP1-92647 and NBP1-92650, which recognize downstream epitopes. Detection: Chemiluminescence with exposure times of 3 minutes (A) and 10 seconds (B).](http://images.novusbio.com/fullsize/USF2-Antibody-Western-Blot-NBP1-92649-img0009.jpg "Western Blot: USF2 Antibody [NBP1-92649] - Detection of human USF2 by western blot and immunoprecipitation. Samples: Whole cell lysate from HeLa (15 and 50 ug for WB; 1 mg for IP, 20% of IP loaded), HEK293T (T; 50 ug) and Jurkat (J; 50 ug) cells. Antibodies: Affinity purified rabbit anti-USF2 antibody NBP1-92649 used for WB at 0.1 ug/ml (A) and 1 ug/ml (B) and used for IP at 6 ug/mg lysate. USF2 was also immunoprecipitated by rabbit anti-USF2 antibodies NBP1-92647 and NBP1-92650, which recognize downstream epitopes. Detection: Chemiluminescence with exposure times of 3 minutes (A) and 10 seconds (B).")
| Reactivity | Hu, Mu, RtSpecies Glossary |
| Applications | WB, IHC, IP, KO |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Concentration | 1.0 mg/ml |
| Immunogen | The immunogen this antibody was made to, maps to a region between residue 1 and 50 of human Upstream Transcription Factor 2 using the numbering given in entry NP_003358.1 (GeneID 7392). |
| Predicted Species | Rat (100%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | USF2 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Application Notes | Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections. |
|
| Publications |
|
| Storage | Store at 4C. Do not freeze. |
| Buffer | Tris-Citrate/Phosphate (pH 7.0 - 8.0) |
| Preservative | 0.09% Sodium Azide |
| Concentration | 1.0 mg/ml |
| Purity | Immunogen affinity purified |
![Simple Western Albumin Antibody (188835) [Unconjugated] - Serum](https://images.novusbio.com/images2/Albumin_MAB1455_Simple_Western_21888.jpg)
![Immunocytochemistry Albumin Antibody (188835) [Unconjugated] - Serum](https://images.novusbio.com/images2/Albumin_MAB1455_Immunocytochemistry__Immunofluorescence_17777.jpg)
![Immunohistochemistry Albumin Antibody (188835) [Unconjugated] - Serum](https://images.novusbio.com/images2/Albumin_MAB1455_Immunohistochemistry_23317.jpg)
Secondary Antibodies |
Isotype Controls |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | USF2 |
![Immunohistochemistry-Paraffin: USF2 Antibody [NBP1-92649] - Sample: FFPE section of mouse renal cell carcinoma. Antibody: Affinity purified rabbit anti- USF2 used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: Hematoxylin (blue).](http://images.novusbio.com/fullsize/USF2-Antibody-Immunohistochemistry-Paraffin-NBP1-92649-img0005.jpg "Immunohistochemistry-Paraffin: USF2 Antibody [NBP1-92649] - Sample: FFPE section of mouse renal cell carcinoma. Antibody: Affinity purified rabbit anti- USF2 used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: Hematoxylin (blue).")
![Immunohistochemistry-Paraffin: USF2 Antibody [NBP1-92649] - FFPE serial sections of human prostate carcinoma.Antibody: Affinity purified rabbit anti- USF2 left image, middle image and right image used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: Hematoxylin (blue).](http://images.novusbio.com/fullsize/USF2-Antibody-Immunohistochemistry-Paraffin-NBP1-92649-img0008.jpg "Immunohistochemistry-Paraffin: USF2 Antibody [NBP1-92649] - FFPE serial sections of human prostate carcinoma.Antibody: Affinity purified rabbit anti- USF2 left image, middle image and right image used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: Hematoxylin (blue).")
![Knockout: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells. Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nbp1-92649_rabbit-polyclonal-usf2-antibody-2552023153953.jpg "Knockout: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells. Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 and sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025/) licensed under a CC-BY license.")
![Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in non-MLLr leukemia cells.(A) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML3 cells. Immunoblotting confirmed the complete depletion of USF2. (B) Immunoblotting confirmed the complete depletion of USF2 in OCI-AML3 cells upon USF2 targeting by a sgRNA. (C) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in U937 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF2 in U937 cells upon USF2 targeting by a sgRNA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-92649_rabbit-polyclonal-usf2-antibody-310202415371996.jpg "Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in non-MLLr leukemia cells.(A) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML3 cells. Immunoblotting confirmed the complete depletion of USF2. (B) Immunoblotting confirmed the complete depletion of USF2 in OCI-AML3 cells upon USF2 targeting by a sgRNA. (C) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in U937 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF2 in U937 cells upon USF2 targeting by a sgRNA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in non-MLLr leukemia cells.(A) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML3 cells. Immunoblotting confirmed the complete depletion of USF2. (B) Immunoblotting confirmed the complete depletion of USF2 in OCI-AML3 cells upon USF2 targeting by a sgRNA. (C) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in U937 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF2 in U937 cells upon USF2 targeting by a sgRNA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-92649_rabbit-polyclonal-usf2-antibody-310202415175229.jpg "Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in non-MLLr leukemia cells.(A) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML3 cells. Immunoblotting confirmed the complete depletion of USF2. (B) Immunoblotting confirmed the complete depletion of USF2 in OCI-AML3 cells upon USF2 targeting by a sgRNA. (C) Q-PCR was performed to validate the transcriptional impact of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in U937 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF2 in U937 cells upon USF2 targeting by a sgRNA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells.(A) Flow cytometry analysis was performed on the HOXA9P2A-mCherry SEM cells targeted with lentiviral Cas9 & sgRNAs against USF1, USF2, & USF1/2 (DKO). (B) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. (C) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in NOMO-1 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF1 in SEM cells upon USF1 targeting by a sgRNA. (E) Immunoblotting confirmed the complete depletion of USF1 in OCI-AML2 cells upon USF1 targeting by a sgRNA. (F) Immunoblotting confirmed the complete depletion of USF2 in MOLM13 cells USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3). (G) Competitive proliferation assay was conducted by infecting MOLM13Cas9 cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) & USF2 (sgUSF2#2, 2#3 & 2#5) at about 50% efficiency. The mCherry% was quantified at days 0, 3, 7, 11, 15, 19, & 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) & the human ROSA26 gene (sgROSA26) were included as negative controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-92649_rabbit-polyclonal-usf2-antibody-310202416113549.jpg "Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells.(A) Flow cytometry analysis was performed on the HOXA9P2A-mCherry SEM cells targeted with lentiviral Cas9 & sgRNAs against USF1, USF2, & USF1/2 (DKO). (B) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. (C) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in NOMO-1 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF1 in SEM cells upon USF1 targeting by a sgRNA. (E) Immunoblotting confirmed the complete depletion of USF1 in OCI-AML2 cells upon USF1 targeting by a sgRNA. (F) Immunoblotting confirmed the complete depletion of USF2 in MOLM13 cells USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3). (G) Competitive proliferation assay was conducted by infecting MOLM13Cas9 cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) & USF2 (sgUSF2#2, 2#3 & 2#5) at about 50% efficiency. The mCherry% was quantified at days 0, 3, 7, 11, 15, 19, & 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) & the human ROSA26 gene (sgROSA26) were included as negative controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: USF2 Antibody [NBP1-92649] - USF2 is required to maintain HOXA9 expression in MLLr leukemia.(A) Flow cytometry analysis was performed at day 8 on the HOXA9P2A-mCherry cells targeted with lentiviral Cas9 & four sgRNAs against USF2. The sgENL-targeted cells were used as positive controls while sgLuc targeted cells were used as negative controls. (B) Q-PCR analysis was conducted on the USF2-targeted cells to monitor the reduction of HOXA9. The sgENL targeted cells were used as positive controls while sgLuc-targeted cells were used as negative controls. Data shown are means ± SEM from three independent experiments. *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t test. (C) Immunoblotting of USF2 in USF2 sgRNAs targeted cells. '*' denoted non-specific bands. (D) USF2 occupancy changes in sgLuc & sgUSF2-targeted SEM cells were characterized in HOXA9 locus (A1, HOXA1; AS3, HOXA-AS3; A7, HOXA7; A9, HOXA9).Time-course knock-down of USF2 & consequent HOXA9 expression analysis.Flow cytometry analysis was performed at day 0, 4, 6, 8, & 11 on the HOXA9P2A-mCherry cells targeted with lentiviral Cas9 & four sgRNAs against USF2. The sgLuc- & sgRosa26-targeted cells were included as negative controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-92649_rabbit-polyclonal-usf2-antibody-310202416121952.jpg "Western Blot: USF2 Antibody [NBP1-92649] - USF2 is required to maintain HOXA9 expression in MLLr leukemia.(A) Flow cytometry analysis was performed at day 8 on the HOXA9P2A-mCherry cells targeted with lentiviral Cas9 & four sgRNAs against USF2. The sgENL-targeted cells were used as positive controls while sgLuc targeted cells were used as negative controls. (B) Q-PCR analysis was conducted on the USF2-targeted cells to monitor the reduction of HOXA9. The sgENL targeted cells were used as positive controls while sgLuc-targeted cells were used as negative controls. Data shown are means ± SEM from three independent experiments. *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t test. (C) Immunoblotting of USF2 in USF2 sgRNAs targeted cells. '*' denoted non-specific bands. (D) USF2 occupancy changes in sgLuc & sgUSF2-targeted SEM cells were characterized in HOXA9 locus (A1, HOXA1; AS3, HOXA-AS3; A7, HOXA7; A9, HOXA9).Time-course knock-down of USF2 & consequent HOXA9 expression analysis.Flow cytometry analysis was performed at day 0, 4, 6, 8, & 11 on the HOXA9P2A-mCherry cells targeted with lentiviral Cas9 & four sgRNAs against USF2. The sgLuc- & sgRosa26-targeted cells were included as negative controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells.(A) Flow cytometry analysis was performed on the HOXA9P2A-mCherry SEM cells targeted with lentiviral Cas9 & sgRNAs against USF1, USF2, & USF1/2 (DKO). (B) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. (C) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in NOMO-1 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF1 in SEM cells upon USF1 targeting by a sgRNA. (E) Immunoblotting confirmed the complete depletion of USF1 in OCI-AML2 cells upon USF1 targeting by a sgRNA. (F) Immunoblotting confirmed the complete depletion of USF2 in MOLM13 cells USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3). (G) Competitive proliferation assay was conducted by infecting MOLM13Cas9 cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) & USF2 (sgUSF2#2, 2#3 & 2#5) at about 50% efficiency. The mCherry% was quantified at days 0, 3, 7, 11, 15, 19, & 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) & the human ROSA26 gene (sgROSA26) were included as negative controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-92649_rabbit-polyclonal-usf2-antibody-31020241612218.jpg "Western Blot: USF2 Antibody [NBP1-92649] - USF2 depletion in MLLr leukemia cells.(A) Flow cytometry analysis was performed on the HOXA9P2A-mCherry SEM cells targeted with lentiviral Cas9 & sgRNAs against USF1, USF2, & USF1/2 (DKO). (B) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in OCI-AML2 cells. Immunoblotting confirmed the complete depletion of USF2. (C) Q-PCR was performed to validate the transcriptional regulation of HOXA9 upon USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3) in NOMO-1 cells. Immunoblotting confirmed the complete depletion of USF2. (D) Immunoblotting confirmed the complete depletion of USF1 in SEM cells upon USF1 targeting by a sgRNA. (E) Immunoblotting confirmed the complete depletion of USF1 in OCI-AML2 cells upon USF1 targeting by a sgRNA. (F) Immunoblotting confirmed the complete depletion of USF2 in MOLM13 cells USF2 targeting by two sgRNAs (sgUSF2#2 & sgUSF2#3). (G) Competitive proliferation assay was conducted by infecting MOLM13Cas9 cells with Lentiviral-mCherry-sgRNAs against luciferase (sgLuc) & USF2 (sgUSF2#2, 2#3 & 2#5) at about 50% efficiency. The mCherry% was quantified at days 0, 3, 7, 11, 15, 19, & 23 by flow cytometry to evaluate the growth disadvantage. A guide RNA targeting the survival essential gene RPS19 was included as a positive control for Cas9 activity. Guide RNAs targeting Luciferase gene (sgLuc) & the human ROSA26 gene (sgROSA26) were included as negative controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33001025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Western_Blot_18923.jpg)
![Immunocytochemistry c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Immunocytochemistry__Immunofluorescence_18945.jpg)
![Simple Western c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Simple_Western_19175.jpg)
![N/A PSG1 [HRP]](https://images.novusbio.com/images2/DATA_PSG1_DPSG10_ELISA_797.jpg)
![N/A PSG1 [HRP]](https://images.novusbio.com/images2/PSG-1_DPSG10_ELISA_164.jpg)
![N/A Hepcidin Antimicrobial Peptide [HRP]](https://images.novusbio.com/images2/Hepcidin_DHP250_ELISA_1121.jpg)
![N/A Hepcidin Antimicrobial Peptide [HRP]](https://images.novusbio.com/images2/Hepcidin_DHP250_ELISA_1122.jpg)
![N/A Thrombospondin-1 [HRP]](https://images.novusbio.com/images2/Thrombospondin-1_DTSP10_ELISA_199.jpg)
![Western Blot Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Western_Blot_5287.jpg)
![Simple Western Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Simple_Western_16990.jpg)
![Knockout Validated Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Knockout_Validated_24032.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")